Agios Pharmaceuticals Inc. (NASDAQ:AGIO)’s share price shot up 3.8% on Wednesday . The company traded as high as $43.14 and last traded at $43.03, with a volume of 567,787 shares changing hands. The stock had previously closed at $41.47.

A number of research firms recently weighed in on AGIO. Canaccord Genuity reiterated a “hold” rating and issued a $50.00 price objective on shares of Agios Pharmaceuticals in a research report on Thursday, June 9th. Vetr lowered shares of Agios Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $68.42 price objective on the stock. in a research report on Tuesday, June 7th. Credit Suisse Group AG reiterated a “buy” rating on shares of Agios Pharmaceuticals in a research report on Monday, April 25th. Zacks Investment Research lowered shares of Agios Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, April 26th. Finally, SunTrust Banks Inc. lifted their price objective on shares of Agios Pharmaceuticals from $57.00 to $65.00 and gave the company a “buy” rating in a research report on Wednesday, May 18th. Six analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $69.67.

The stock’s market capitalization is $1.63 billion. The stock has a 50-day moving average of $50.09 and a 200-day moving average of $47.14.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings results on Thursday, May 5th. The biopharmaceutical company reported ($0.61) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.79) by $0.18. During the same period in the prior year, the company posted ($0.13) earnings per share. The firm had revenue of $31.30 million for the quarter, compared to analyst estimates of $20.94 million. The business’s revenue was down 8.5% on a year-over-year basis. On average, analysts forecast that Agios Pharmaceuticals Inc. will post ($3.46) earnings per share for the current fiscal year.

In related news, Director Lewis Clayton Jr. Cantley sold 627 shares of the company’s stock in a transaction on Monday, April 25th. The stock was sold at an average price of $55.00, for a total transaction of $34,485.00. Following the completion of the transaction, the director now directly owns 128,429 shares in the company, valued at approximately $7,063,595. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, insider Scott Biller sold 27,500 shares of the company’s stock in a transaction on Wednesday, June 8th. The stock was sold at an average price of $65.00, for a total value of $1,787,500.00. Following the transaction, the insider now owns 81,376 shares of the company’s stock, valued at $5,289,440. The disclosure for this sale can be found here.

A number of hedge funds and institutional investors recently modified their holdings of the company. Mutual of America Capital Management LLC increased its position in shares of Agios Pharmaceuticals by 0.5% in the fourth quarter. Mutual of America Capital Management LLC now owns 17,325 shares of the biopharmaceutical company’s stock worth $1,125,000 after buying an additional 86 shares during the last quarter. Rhumbline Advisers increased its position in shares of Agios Pharmaceuticals by 2.5% in the fourth quarter. Rhumbline Advisers now owns 24,947 shares of the biopharmaceutical company’s stock worth $1,620,000 after buying an additional 605 shares during the last quarter. State Board of Administration of Florida Retirement System increased its position in shares of Agios Pharmaceuticals by 7.7% in the fourth quarter. State Board of Administration of Florida Retirement System now owns 22,672 shares of the biopharmaceutical company’s stock worth $1,472,000 after buying an additional 1,624 shares during the last quarter. ProShare Advisors LLC increased its position in shares of Agios Pharmaceuticals by 5.9% in the fourth quarter. ProShare Advisors LLC now owns 31,258 shares of the biopharmaceutical company’s stock worth $2,029,000 after buying an additional 1,740 shares during the last quarter. Finally, GAM Holding AG increased its position in shares of Agios Pharmaceuticals by 210.9% in the fourth quarter. GAM Holding AG now owns 45,700 shares of the biopharmaceutical company’s stock worth $2,967,000 after buying an additional 31,000 shares during the last quarter.

Agios Pharmaceuticals, Inc (Agios) is a biopharmaceutical company. The Company is engaged in the discovery and development of orally available small molecule medicines for the treatment of cancer and rare genetic disorders (RGDs) of metabolism using cellular metabolism as a platform. It is also engaged in the identification and validation of altered metabolic pathways within abnormal cells.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.